Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 11:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 653 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Total Cholesterol Clear all

Conditions: Hyperlipidemia
Interventions: Enlicitide, Rosuvastatin, Placebo for Enlicitide, Placebo for Rosuvastatin; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 996 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 35
States / cities: Birmingham, Alabama • Foley, Alabama • Phoenix, Arizona + 30 more

Conditions: Acute Coronary Syndrome
Interventions: dalcetrapib, Placebo; Drug
Lead sponsor: DalCor Pharmaceuticals; Industry
Eligibility: 45 Years and older
Enrollment: 6,147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 122
States / cities: Alexander City, Alabama • Huntsville, Alabama • Mobile, Alabama + 119 more

Conditions: Familial Hypercholesterolemia, Cholesterol, Elevated, Genetic Disease
Interventions: Motivational interview (MI); Behavioral
Lead sponsor: Essentia Health; Other
Eligibility: 2 Years to 75 Years
Enrollment: 257 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Duluth, Minnesota

Conditions: Lysosomal Acid Lipase Deficiency
Interventions: Sebelipase Alfa, Placebo; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 4 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 11
States / cities: Tucson, Arizona • Palo Alto, California • San Francisco, California + 8 more

Conditions: Colorectal Cancer
Interventions: EGEN-001-301; Drug
Lead sponsor: EGEN, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Zion, Illinois

Conditions: Dyslipidemia
Interventions: Oleic Diet, Palmitic Diet, Stearic Diet; Other
Lead sponsor: Tufts University; Other
Eligibility: 50 Years to 85 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cognitively Normal Older Adults, Hypertension, Subjective Cognitive Decline, Family History of Alzheimer's Disease
Interventions: Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine), Aerobic Exercise Training, Usual Care, Stretching Exercise; Drug · Behavioral · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 60 Years to 85 Years
Enrollment: 513 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 4
States / cities: Kansas City, Kansas • Baton Rouge, Louisiana • St Louis, Missouri + 1 more

Conditions: Spinal Cord Injuries, Obesity, Cardiometabolic Syndrome
Interventions: Telenutrition; Behavioral
Lead sponsor: Santa Clara Valley Health & Hospital System; Other
Eligibility: 20 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: San Jose, California

Conditions: Healthy
Interventions: 3H-Cholesterol; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Dyslipidemias
Interventions: Niacin, Placebo; Drug · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 75 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetes
Interventions: Adherence information, Adherence information plus motivational interviewing; Behavioral
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 1,692 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Overweight, Childhood Obesity
Interventions: Attention to BMI, Attention to high-BMI-related Medical Risk, No attention to high BMI or high-BMI-related medical risk; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 6 Years to 12 Years
Enrollment: 7,192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Weight Loss
Interventions: Shared Medical Visits, Full Plate Living; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Dyslipidemia
Interventions: AZD0780, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 14
States / cities: Huntsville, Alabama • Lincoln, California • Palm Springs, California + 11 more

Conditions: Hypercholesterolemia, Dyslipidemia
Interventions: PF-04950615 (RN316); Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 9
States / cities: Culver City, California • Glendale, California • Miami, Florida + 4 more

Conditions: Breast Cancer, Breast Tumors, Cancer of Breast
Interventions: Metformin, Atorvastatin, Breast surgery; Drug · Procedure
Lead sponsor: Columbia University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Pregnancy Related
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Type 2 Diabetes, Overweight and Obese Adults
Interventions: Low-fat, vegan diet; Behavioral
Lead sponsor: Physicians Committee for Responsible Medicine; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Hyperlipidemias, Metabolic Syndrome X, Cardiovascular Diseases
Interventions: Comparison of dietary protein amino acid profile; Behavioral
Lead sponsor: Tufts University; Other
Eligibility: 50 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prostate Cancer
Interventions: ezetimibe 10mg-simvastatin 40mg; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HIV Infections, Hyperlipidemia
Interventions: oyster mushroom; Drug
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hyperlipidemia
Interventions: ETC-1002, Atorvastatin, Placebo; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 19
States / cities: Anaheim, California • Los Angeles, California • Northridge, California + 16 more

Conditions: Hypercholesterolemia, Familial
Interventions: ISIS 301012 or Placebo; Drug
Lead sponsor: Kastle Therapeutics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 7
States / cities: Chicago, Illinois • Auburn, Maine • Scarborough, Maine + 4 more

Conditions: Severe Asthma
Interventions: Simvastatin, Placebo; Drug · Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Sacramento, California

Search by objective public record fields.

A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)

Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

Improved Diagnosis of Familial Hypercholesterolemia Across the Northland (ID-FH)

Acid Lipase Replacement Investigating Safety and Efficacy (ARISE) in Participants With Lysosomal Acid Lipase Deficiency

A Study of the Safety and Biological Activity of Intraperitoneal (IP) EGEN-001 Administered Alone and in Combination With Standard Chemotherapy in Colorectal Peritoneal Carcinomatosis Patients

Development of a Novel Method to Study in Vivo Fatty Acid Metabolism Using Stable Isotope Labeled Fatty Acids in Humans

Risk Reduction for Alzheimer's Disease

Telenutrition for Individuals With SCI

BMS Reverse Cholesterol Transport (RCT) Study

Effect of Niacin on Transport of HDL and Relationship to Atherogenic Lipoproteins and Lipolysis

Multi-arm Intervention Diabetes Adherence Study

Primary Care Clinical Practice Elements and Improving Overweight Children's Weight Status

Food is Medicine: Pilot Study

A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia

Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia

Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer

Cholesterol and CYP3A4/5 Metabolism Across Pregnancy and Postpartum

Plant-Based Online Weight Loss Through Education and Resources Program and Study

Effect of Dietary Amino Acid Profile on Lipoprotein Metabolism, Vascular Reactivity and Inflammatory Markers

Cellular Effect of Cholesterol-Lowering Prior to Prostate Removal

Antihyperlipidemic Effects of Oyster Mushrooms

A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg

Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy

Trial of Simvastatin for the Treatment of Severe Asthma